481 related articles for article (PubMed ID: 11034587)
1. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
Zylberberg H; Benhamou Y; Lagneaux JL; Landau A; Chaix ML; Fontaine H; Bochet M; Poynard T; Katlama C; Pialoux G; Bréchot C; Pol S
Gut; 2000 Nov; 47(5):694-7. PubMed ID: 11034587
[TBL] [Abstract][Full Text] [Related]
2. [Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy].
Ke YC; Li LH; Hu FY; He Y; Lan Y; Chen XJ; Tang XP; Cai WP
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):181-5. PubMed ID: 27095760
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
4. Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Milazzo L; Foschi A; Mazzali C; Viola A; Ridolfo A; Galli M; Antinori S
AIDS Res Hum Retroviruses; 2012 Sep; 28(9):989-93. PubMed ID: 22220723
[TBL] [Abstract][Full Text] [Related]
5. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Núñez M; Ocampo A; Aguirrebengoa K; Cervantes M; Pascual A; Echeverria S; Asensi V; Barreiro P; Garcia-Samaniego J; Soriano V;
J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
Mira JA; Gutiérrez-Valencia A; Gil Ide L; Merino D; Rivero A; Ríos-Villegas MJ; Delgado M; González-Serrano M; Collado A; Torres-Tortosa M; Omar M; López-Ruz MA; Macías J; Arponen S; Pineda JA
Clin Infect Dis; 2009 Oct; 49(8):e84-91. PubMed ID: 19772388
[TBL] [Abstract][Full Text] [Related]
8. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
Bräu N
Semin Liver Dis; 2005 Feb; 25(1):33-51. PubMed ID: 15731996
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients.
Landau A; Batisse D; Duong Van Huyen JP; Piketty C; Bloch F; Pialoux G; Belec L; Petite JP; Weiss L; Kazatchkine MD
AIDS; 2000 May; 14(7):839-44. PubMed ID: 10839592
[TBL] [Abstract][Full Text] [Related]
11. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders.
Sauleda S; Juárez A; Esteban JI; Altisent C; Ruiz I; Puig L; Esteban R; Guardia J
Hepatology; 2001 Nov; 34(5):1035-40. PubMed ID: 11679976
[TBL] [Abstract][Full Text] [Related]
12. [Discussion on optimal duration of pegylated interferon α combined with ribavirin for chronic hepatitis C in HIV-infected patients].
Ke YC; Li LH; Hu FY; Lan Y; He YZ; Chen XJ; Tang XP; Cai WP; Lu RC; He Y; Li HQ
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):282-287. PubMed ID: 29996340
[No Abstract] [Full Text] [Related]
13. Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
Bani-Sadr F; Goderel I; Penalba C; Billaud E; Doll J; Welker Y; Cacoub P; Pol S; Perronne C; Carrat F;
J Viral Hepat; 2007 Sep; 14(9):639-44. PubMed ID: 17697016
[TBL] [Abstract][Full Text] [Related]
14. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
Bräu N
J Antimicrob Chemother; 2005 Dec; 56(6):991-5. PubMed ID: 16308419
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
Seydi M; Morlat P; Bonnet F; Rambeloarisoa J; Bernard N; Lacoste D; Bonarek M; Trimoulet P; Ramanampamonjy R; Lafon ME; Dramé M; Beylot J
Rev Med Interne; 2005 Apr; 26(4):280-7. PubMed ID: 15820563
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients.
Neau D; Trimoulet P; Winnock M; Rullier A; Le Bail B; Lacoste D; Ragnaud JM; Bioulac-Sage P; Lafon ME; Chêne G; Dupon M;
Clin Infect Dis; 2003 Jun; 36(12):1564-71. PubMed ID: 12802757
[TBL] [Abstract][Full Text] [Related]
17. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
20. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
